2009-11-24 12:08:02 -

ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that Douglas E.

Williams, Ph.D., Chief Executive Officer of ZymoGenetics, will provide an update on company activities at the Piper Jaffray Healthcare Conference in New York City on Wednesday, December 2, 2009 at 8:30 a.m.

Eastern Time.

A live webcast of the presentation can be accessed by going to: www.zymogenetics.com : .

The webcast will be archived for 30 days.



About ZymoGenetics

ZymoGenetics is focused on the creation of novel protein drugs to improve patient care and address unmet medical needs. The company’s strategy is to discover, develop and commercialize its products independently, in collaboration with partner companies or through out-licensing. ZymoGenetics developed and markets RECOTHROM ® Thrombin,

topical (Recombinant), a synthetic version of a human blood-clotting enzyme used to stop bleeding during surgery. The company is developing a proprietary portfolio of immune-based product candidates. PEG-Interferon lambda is a novel type-3 interferon in clinical development for the treatment of chronic hepatitis C infection.
Interleukin-21 is a novel cytokine in clinical development for the treatment of metastatic melanoma and renal cell carcinoma. Several other proprietary product candidates are in preclinical development. In addition, ZymoGenetics has licensed rights to multiple clinical and preclinical drug candidates being developed by other companies. For further information, visit www.zymogenetics.com : .



Investor and Media ContactZymoGenetics, Inc.Director,

Corporate CommunicationsSusan W. Specht, 206-442-6592